EFPIA Pharmaceutical Industry

The European Federation of Pharmaceutical Industries and Associations (EFPIA) The Pharmaceutical Research and Manufacturers of America (PhRMA)... 

European Federation of Pharmaceutical Industries and Associations (EFPIA)... 

The EFPIA is situated in Brussels and has, as its members, 25 national pharmaceutical industry associations and leading pharmaceutical companies. Much of the Federation s work is concerned with the activities of the European Commission and the new EMEA. 

European Federation of Pharmaceutical Industries Associations. European Code of Practice for the Promotion of Medicines, 2nd edn. Brussels EFPIA, 1992. 

Following extensive discussions among aU interested parties, such as the national authorities, the EC and the European Federation of Pharmaceutical Industries and Associations (EFPIA), the EC proposed comprehensive reform of the EU pharmaceutical legislation. The amending legislations are ... 

European Federation of Pharmaceutical Industries and Associations (EFPIA) With EFPIA membership from sixteen countries in Western Europe, including all of Europe s major research-based pharmaceutical companies, the Federation s work is concerned with the activities of the EMEA. A wide network of experts and country coordinators has been established to ensure that EFPIA s views are represented in ICH guidelines. 

One of the key elements for its success is most probably the composition of the organization. It was founded in 1990 as a joint regulatory/industry initiative. The six cosponsors are the EC and the EFPIA (European Federation of Pharmaceutical Industries Association) for the EU, the MHLW and JPMA (Japan Pharmaceutical Manufacturers Association) for Japan, and the U.S. FDA and PhRMA (Pharmaceutical Research and Manufacturers of America) for the United States. 

To quote The European Federation of Pharmaceutical Industries and Associations (EFPIA) Policy Statement on the use of animals in research and development, as our biological knowledge increases, so too does the usefulness of nonanimal methods. There are still enormous gaps in our biological knowledge that limit the usefulness of cell culture and computer based research . 

The International Conferences was jointly supported and organized by the Commission of the European Communities (CEC), the US Food and Drug Administration (FDA), the Japanese Ministry of Health and Welfare (MHW), together with the pharmaceutical industry, as represented by the International Federation of Pharmaceutical Manufacturers Associations (IFPMA), the European Federation of Pharmaceutical Industry Associations (EFPIA), the US Pharmaceutical Manufacturers Association (PMA) and the Japanese Pharmaceutical Manufacturers Association (PMA). 

ICH 1, the first international ICH meeting, was held in Brussels in November of 1991. This meeting, sponsored by the Commission of the European Communities and the European Federation of Pharmaceutical Industries Associations (EFPIA), was composed of three parallel workshops on the topics of Quality, Safety, and Efficacy and identified 11 topics for harmonization. 

In the case of promotion that is undertaken, sponsored or organised by a company located outside Europe, the EFPIA (European Federation Pharmaceutical Industry Association) code... 

The Swiss Pharmaceutical Industry has a self-regulatory code of conduct the Pharma code. This code takes into account, in particular, the codes issued by the IFPMA and the EFPIA, as well as the recommendations of the Swiss Academy of Medical Sciences relating to collaboration between the medical profession and the industry. In addition, the provisions of the Federal Law against Unfair Competition of 1986 must be observed. 

Six founding members of ICH are directly involved in the decision-making process. They represent the regulatory bodies and the industry in the European Union, Japan, and the United States. They are the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA) in Europe the Ministry of Health Labor and Welfare and the Japan Pharmaceutical Manufacturers Association (JPMA) in Japan the FDA and the Pharmaceutical Research and Manufacturers of America (PhRMA) and a group of observers including WHO, The European Free Trade Area (EFTA represented at ICH by Swissmedic Switzerland), and Canada represented by Health Canada. 

---